BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Thyroid cancer AND TRRAP, TR-AP, 8295, ENSG00000196367, Q9Y4A5, PAF400, PAF350/400, FLJ10671, STAF40, Tra1 AND Prognosis
35 results:

  • 1. Second radioiodine treatment in patients with differentiated thyroid carcinoma: Causes and effects.
    Sicilia Pozo MLN; Pena Pardo FJ; Amo Salas M; Cruz Montijano M; Torres Hernández J; Padilla Bermejo A; Montalbán Méndez C; Zhao Montero M; Soriano Castrejón Á; García Vicente AM
    Endocrinol Diabetes Nutr (Engl Ed); 2024 Jan; 71(1):4-11. PubMed ID: 38388076
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Risk factors for central lymph node metastasis in patients with papillary thyroid carcinoma: a retrospective study.
    Du J; Yang Q; Sun Y; Shi P; Xu H; Chen X; Dong T; Shi W; Wang Y; Song Z; Shang X; Tian X
    Front Endocrinol (Lausanne); 2023; 14():1288527. PubMed ID: 38047112
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Risk factors and survival prediction of young breast cancer patients with liver metastases: a population-based study.
    Pu CC; Yin L; Yan JM
    Front Endocrinol (Lausanne); 2023; 14():1158759. PubMed ID: 37424855
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Prognostic value of the preoperative and early trends in postoperative serum thyroglobulin antibody levels among patients with papillary thyroid carcinoma and concomitant Hashimoto's thyroiditis.
    Xu S; Huang H; Qian J; Wang X; Xu Z; Liu S; Liu J
    Endocrine; 2023 May; 80(2):392-398. PubMed ID: 36534327
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Differential diagnosis of non-diffuse primary thyroid lymphoma and papillary thyroid carcinoma by ultrasound combined with computed tomography.
    Peng C; Yi D; Zhou Y; Yao J; Chen B; Yang C; Xu D
    BMC Cancer; 2022 Aug; 22(1):938. PubMed ID: 36042430
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. An Underdiagnosed Hypothyroidism and Its Clinical Significance in Patients with Advanced Hepatocellular Carcinoma.
    Shao YY; Cheng AL; Hsu CH
    Oncologist; 2021 May; 26(5):422-426. PubMed ID: 33687750
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Analysis of Biomarkers and Association With Clinical Outcomes in Patients With Differentiated thyroid cancer: Subanalysis of the Sorafenib Phase III DECISION Trial.
    Brose MS; Schlumbeger M; Jeffers M; Kappeler C; Meinhardt G; Peña CEA
    Clin Cancer Res; 2019 Dec; 25(24):7370-7380. PubMed ID: 31558473
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. First Line Sorafenib Treatment for Metastatic Medullary thyroid cancer: Efficacy and Safety Analysis.
    Kocsis J; Szekanecz É; Bassam A; Uhlyarik A; Pápai Z; Rubovszky G; Mezősi E; Rucz K; Garai I; Nagy E; Uray I; Horváth Z
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):240-246. PubMed ID: 29506310
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Assessment of risk factors in metastatic/recurrent tall cell variant of papillary thyroid carcinoma.
    Okuyucu K; Alagoz E; Ince S; Arslan N
    Endokrynol Pol; 2017; 68(6):623-630. PubMed ID: 29022644
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Prognostic and Predictive Value of thyroid Transcription Factor-1, CD56, P40 and Other Clinical Characteristics in Small Cell Lung cancer Patients].
    Wang X; Zhang Y; Hu M; Wang R; Liu L; Qian K; Li Y; Zhi X
    Zhongguo Fei Ai Za Zhi; 2017 Aug; 20(8):522-527. PubMed ID: 28855032
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. TERT promoter mutations and Ki-67 labeling index as a prognostic marker of papillary thyroid carcinomas: combination of two independent factors.
    Matsuse M; Yabuta T; Saenko V; Hirokawa M; Nishihara E; Suzuki K; Yamashita S; Miyauchi A; Mitsutake N
    Sci Rep; 2017 Feb; 7():41752. PubMed ID: 28150740
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Combined fibrinogen and neutrophil-lymphocyte ratio as a prognostic marker of advanced esophageal squamous cell carcinoma.
    Kijima T; Arigami T; Uchikado Y; Uenosono Y; Kita Y; Owaki T; Mori S; Kurahara H; Kijima Y; Okumura H; Maemura K; Ishigami S; Natsugoe S
    Cancer Sci; 2017 Feb; 108(2):193-199. PubMed ID: 27889946
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Human epidermal growth factor receptor 4 (HER4) is a favorable prognostic marker of breast cancer: a systematic review and meta-analysis.
    Wang J; Yin J; Yang Q; Ding F; Chen X; Li B; Tian X
    Oncotarget; 2016 Nov; 7(47):76693-76703. PubMed ID: 27736797
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. A Novel Scoring System Based on Fibrinogen and the Neutrophil-Lymphocyte Ratio as a Predictor of Chemotherapy Response and prognosis in Patients with Advanced Gastric cancer.
    Arigami T; Uenosono Y; Ishigami S; Okubo K; Kijima T; Yanagita S; Okumura H; Uchikado Y; Kijima Y; Nakajo A; Kurahara H; Kita Y; Mori S; Maemura K; Natsugoe S
    Oncology; 2016; 90(4):186-92. PubMed ID: 26981856
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Prognostication by inflammation-based score in patients with locally advanced pancreatic cancer treated with chemoradiotherapy.
    Kurahara H; Maemura K; Mataki Y; Sakoda M; Iino S; Hiwatashi K; Kawasaki Y; Arigami T; Ishigami S; Kijima Y; Shinchi H; Takao S; Natsugoe S
    Pancreatology; 2015; 15(6):688-93. PubMed ID: 26500167
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Analysis of the Fibrinogen and Neutrophil-Lymphocyte Ratio in Esophageal Squamous Cell Carcinoma: A Promising Blood Marker of Tumor Progression and prognosis.
    Arigami T; Okumura H; Matsumoto M; Uchikado Y; Uenosono Y; Kita Y; Owaki T; Mori S; Kurahara H; Kijima Y; Ishigami S; Natsugoe S
    Medicine (Baltimore); 2015 Oct; 94(42):e1702. PubMed ID: 26496280
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial.
    Brose MS; Nutting CM; Jarzab B; Elisei R; Siena S; Bastholt L; de la Fouchardiere C; Pacini F; Paschke R; Shong YK; Sherman SI; Smit JW; Chung J; Kappeler C; Peña C; Molnár I; Schlumberger MJ;
    Lancet; 2014 Jul; 384(9940):319-28. PubMed ID: 24768112
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Sorafenib in metastatic thyroid cancer.
    Capdevila J; Iglesias L; Halperin I; Segura A; Martínez-Trufero J; Vaz MÁ; Corral J; Obiols G; Grande E; Grau JJ; Tabernero J
    Endocr Relat Cancer; 2012 Apr; 19(2):209-16. PubMed ID: 22285864
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Long-term outcomes of distant metastasis from differentiated thyroid carcinoma.
    Huang IC; Chou FF; Liu RT; Tung SC; Chen JF; Kuo MC; Hsieh CJ; Wang PW
    Clin Endocrinol (Oxf); 2012 Mar; 76(3):439-47. PubMed ID: 21950769
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Descriptive epidemiology of thyroid cancer in France: incidence, mortality and survival.
    Colonna M; Bossard N; Guizard AV; Remontet L; Grosclaude P;
    Ann Endocrinol (Paris); 2010 Mar; 71(2):95-101. PubMed ID: 20036351
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.